

Chronic Lymphocytic Leukemia

Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina

Trial Status Completed	Trial Runs In 1 Countries	Trial Identifier NCT03059251 ML30187
----------------------------------	-------------------------------------	--

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This observational study aims to study the effectiveness and safety of Obinutuzumab in common clinical practice settings in Argentina. The study population comprises all patients with chronic lymphocytic leukemia (CLL) that have received the indication for treatment with Obinutuzumab as per routine clinical practice.

Hoffmann-La Roche Sponsor	N/A Phase
-------------------------------------	---------------------

NCT03059251 ML30187
Trial Identifiers

Eligibility Criteria:

Gender All	Age ≥18 Years	Healthy Volunteers No
----------------------	-------------------------	---------------------------------
